| Objective:Immunology research has shown that the generate, development and prognosis of tumor are related closely to immunity. In this study, peripheral blood of patients is measured to understand T cell subsets, B lymphocytes and NK cell levels of tumor patients. And to study the Aidi injection on the impact of T lymphocyte subsets, B lymphocytes and NK cell levels in peripheral blood of tumor patients.At the same time, Aidi injection were observed the effect on the quality of life, bone marrow suppression and gastrointestinal reaction of cancer patients.Methods:60 tumor patients who are confirmed by cytology and histopathology, exclude people with autoimmune diseases, immune deficiency, hypersensitivity disease or recent patients receiving immunosuppressive therapy and all the patients were selected from Tianjin Nankai Hospital during May 2009 to February 2010. Selecting 30 healthy subjects as control group were measured in peripheral blood T lymphocyte subsets, B lymphocytes and NK cell level for statistical comparison; 46 tumor patients who received surgery treatment were randomly divided into two groups, one group received chemotherapy alone,another group of chemotherapy based on Aidi injection treatment.Collecting to determine T lymphocyte subsets, B lymphocytes and NK cell levels for statistical comparisons after two courses of peripheral blood. We also observe the effect of Aidi injection on quality of life of patients and bone marrow suppression and gastrointestinal.Results:1 Healthy subjects CD3+, CD4+T lymphocyte levels and CD4+/CD8+ significantly higher than the tumor group (P<0.01); B lymphocytes and NK cells was higher than tumor group, the difference was statistically significant (P< 0.05); healthy subjects peripheral blood CD8+ cells was significantly lower than the tumor group (P<0.05).2 After two cycles of chemotherapy, chemotherapy combined with Aidi group after treatment was higher than in peripheral blood CD3+ chemotherapy group, the difference was statistically significant (P<0.05); peripheral blood CD4+T lymphocyte levels and CD4+/CD8+ significantly higher than the chemotherapy alone group (P<0.01); CD8+T lymphocyte levels of the two groups after treatment, no significant statistical difference (P>0.05); B lymphocytes and NK cell levels in Aidi group was slightly higher than the chemotherapy group, however, no statistically significant difference (P>0.05). Eddie was the treatment group after two courses3 Aidi group patients who were treated after two courses, KPS increased in 17 cases, no change in 3 cases, the deterioration in 3 cases. Patients treatment KPS increased in 10 cases, no change in 8 cases, the general deterioration in 5 patients after chemotherapy. The statistics revealed that the two groups KPS showed significant difference(χ2=4.39, P<0.05); Aidi group and the chemotherapy group was no significant difference in body weight (χ2=0.35, P>0.05)4 Aidi group leukopenia rate was 43.48%,Ⅲ,Ⅳdegree of inhibition rate was 8.70%, and leukopenia in chemotherapy group rate was 73.91%,Ⅲ,Ⅳdegree of bone marrow inhibition rate was 21.73%, leukopenia rate between the two groups was significant difference (χ2=4.39, P<0.05), while the two groupsⅢ,Ⅳdegree of bone marrow suppression was no significant difference in the incidence of significant (χ2=0.67, P>0.05). Aidi group and the chemotherapy group of hemoglobin, the incidence of thrombocytopenia andⅢ,Ⅳdegree of bone marrow suppression was no significant difference in the incidence of significant (P>0.05).5 Aidi group the incidence of gastrointestinal symptoms compared with the chemotherapy alone group had no significant statistical difference (χ2= 0.89, P> 0.05), but Aidi groupⅢ,Ⅳdegree of gastrointestinal tract were significantly lower than the chemotherapy alone group difference between two groups was statistically significant (χ2=3.60, P<0.05).Conclusion:1 Immune function in patients with malignant tumors was significantly lower than healthy people.2 Aidi injection can improve immune function in patients with malignant tumors.3 Aidi injection can improve the quality of life of cancer patients.4 Aidi injection can significantly reduce the side effects produced by chemotherapy, systemic chemotherapy in patients with increased tolerance. |
PDF Full Text Request